1.SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals

She, KL, Fang, SH, D     More...

She, KL, Fang, SH, Du, W, Fan, XX, He, JX, Pan, H, Huang, LY, He, P, Huang, J     Less

CANCER CELL INTERNATIONAL[1475-2867], Published 2019, Volume 19, Issue 1,

收錄情况： WOS SCOPUS

WOS核心合集引用: 64  2025影響因子:  7.0  发表年影響因子:  4.175 

2.p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling

Zhang, YZ, Han, CY,     More...

Zhang, YZ, Han, CY, Duan, FG, Fan, XX, Yao, XJ, Parks, RJ, Tang, YJ, Wang, MF, Liu, L, Tsang, BK, Leung, ELH     Less

CANCER CELL INTERNATIONAL[1475-2867], Published 2019, Volume 19, Issue 1,

收錄情况： WOS SCOPUS

WOS核心合集引用: 60  2025影響因子:  7.0  发表年影響因子:  4.175 

3.APLP2 as a Molecular Link Between Immune Regulation and Bone Metabolism in Hepatocellular Carcinoma: Evidence from scRNA-Seq and Functional Validation

Zhen Liang, Jinchang     More...

Zhen Liang, Jinchang Zheng, Zhanpeng Su, Bo Wu, Haina Yang, Shuyou Bai,, Xinyuan Wu, Chong Sun, Litao Duan, Shaoru Chen, Bo Wei, Xingxing Fan, Sien Lin     Less

Cancer Cell International[1475-2867], Published 2026,

2025影響因子:  7.0